• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 957127 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414293803 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414293803 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Acadia Pharmaceuticals Bullish Moving Average Crossover Alert (ACAD)

Published on Thu, 05/15/2014 - 13:19
By Peter Chu

Today, shares of Acadia Pharmaceuticals (NASDAQ:ACAD) have crossed bullishly above their 10-day moving average of $19.04 on a volume of 954K shares. This may provide swing traders with an opportunity for a long position, as such a crossover often suggests higher prices in the near term.

Acadia Pharmaceuticals share prices have moved between a 52-week high of $32.00 and a 52-week low of $11.81 and are now trading 63% above that low price at $19.23 per share. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 2.6%.

Acadia Pharmaceuticals has overhead space with shares priced $19.23, or 42.1% below the average consensus analyst price target of $33.20. The stock should run into initial resistance at its 50-day moving average (MA) of $22.47 and subsequent resistance at its 200-day MA of $23.17.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Shares of Travelers Rise Above Previous ...

Shares of Travelers (NYSE:TRV) traded today at $97.70, breaking its 52-week high. Appr ...

Shares of Transglobe Energy Fall to a Ne...

Transglobe Energy (NASDAQ:TGA) traded today at a new 52-week low of $4.66. So far toda ...

Shares of Teleflex Have Risen Above Prev...

Shares of Teleflex (NYSE:TFX) traded today at $111.56, breaking its 52-week high. Appr ...

Southwest Gas: 52-Week High Recently Ecl...

Southwest Gas (NYSE:SWX) traded today at a new 52-week high of $56.15. So far today ap ...

Shares of Southwestern Energy Have Falle...

Shares of Southwestern Energy (NYSE:SWN) traded at a new 52-week low today of $31.28. ...

Shares of Sovran Self Storage Rise to a ...

Shares of Sovran Self Storage (NYSE:SSS) traded today at $82.98, breaking its 52-week h ...

Recent 52-Week High Exceeded in Shares o...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.92. So far today approxi ...

Super Micro Computer: The Winning Streak...

Super Micro Computer (NASDAQ:SMCI) traded today at a new 52-week high of $31.00. This ...